Biogen (BIIB) Stock: $185 Price Target From Wedbush

By Amit Chowdhry ● Apr 9, 2022
  • The shares of Biogen Inc (NASDAQ: BIIB) have received a $185 price target from Wedbush. These are the details.

The shares of Biogen Inc (NASDAQ: BIIB) have received a $185 price target from Wedbush. And Wedbush analyst Laura Chico is maintaining a “Neutral” rating on the shares.

Chico adjusted the rating after the CMS release of policy for coverage of Aduhelm in treating Alzheimer’s disease. And the final memo looks similar to the initial memo released in January as Chico sees a daunting road ahead for Aduhelm and Biogen. 

Plus Chico struggles to see a compelling forward growth strategy.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.